The first patient has been dosed in a Phase 2 trial assessing the safety and preliminary efficacy of PVSRIPO in combination with Keytruda (pembrolizumab) as a treatment for people with recurrent glioblastoma multiforme (rGBM), an aggressive form of brain cancer. The open-label study, called LUMINOS-101 (NCT04479241), aims to enroll around 30 adults with rGBM from several clinical sites across the U.S. More information about trial contacts and recruiting sites can be found here. The 24-month study…
You must be logged in to read/download the full post.
The post First Glioblastoma Patient Dosed in Phase 2 Trial Testing PVSRIPO Plus Keytruda appeared first on BioNewsFeeds.